Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 1. Annual reported cases of notifiable diseases and rates per 100,000, excluding U.S. Territories - - United States, 2018
Disease Case Count Rate
Anthrax 1 0.00
Arboviral diseases
Chikungunya virus disease 117 0.04
Eastern equine encephalitis virus disease
Neuroinvasive 6 0.00
Non-neuroinvasive — —
Jamestown Canyon virus disease
Neuroinvasive 25 0.01
Non-neuroinvasive 16 0.00
La Crosse virus disease
Neuroinvasive 83 0.03
Non-neuroinvasive 3 0.00
Powassan virus disease
Neuroinvasive 21 0.01
Non-neuroinvasive — —
St. Louis encephalitis virus disease
Neuroinvasive 5 0.00
Non-neuroinvasive 3 0.00
West Nile virus disease
Neuroinvasive 1,657 0.51
Non-neuroinvasive 989 0.30
Western equine encephalitis virus disease
Neuroinvasive — —
Non-neuroinvasive — —
Babesiosis
Total 2,160 0.79
Confirmed 1,861 0.68
Probable 299 0.11
Botulism
Total 225 0.07
Foodborne 17 0.01
Infant 157 4.08
Other (wound & unspecified) 51 0.02
Brucellosis 138 0.04
Campylobacteriosis 70,200 21.46
Chancroid 3 0.00
Chlamydia trachomatis infection 1,758,668 537.54
Cholera 14 0.00
Coccidioidomycosis * 15,611 11.58
Cryptosporidiosis
Total 12,533 3.83
Confirmed 8,980 2.74
Probable 3,553 1.09
Cyclosporiasis 3,519 1.20
Dengue virus infections †
Dengue 424 0.13
Dengue-like illness 41 0.01
Severe dengue 9 0.00
Diphtheria 1 0.00
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 4,008 1.27
Ehrlichia chaffeensis infection 1,799 0.57
Ehrlichia ewingii infection 33 0.01
Undetermined ehrlichiosis/anaplasmosis 283 0.09
Giardiasis 15,548 6.06
Gonorrhea 583,405 178.32
Haemophilus influenzae, invasive disease
All ages, all serotypes 5,573 1.70
Age <5 years
Serotype b 38 0.19
Non-b serotype 191 0.96
Nontypeable 222 1.12
Unknown serotype 175 0.88
Hansen's disease 90 0.03
Hantavirus infection, non-hantavirus pulmonary syndrome 2 0.00
Hantavirus pulmonary syndrome 18 0.01
Hemolytic uremic syndrome post-diarrheal 376 0.12
Hepatitis §
A, acute 12,474 3.81
B, acute 3,322 1.02
B, perinatal infection 23 0.30
C, acute 4,768 1.54
Confirmed 3,621 1.17
Probable 1,147 0.37
C, perinatal infection 214 0.07
Human immunodeficiency virus diagnoses 32,999 10.09
Influenza-associated pediatric mortality 159 0.22
Invasive pneumococcal disease 
All ages 19,857 8.14
Confirmed 19,619 8.04
Probable 238 0.10
Age <5 years 1,116 0.43
Confirmed 1,078 6.80
Probable 38 0.24
Legionellosis 9,933 3.04
Leptospirosis 91 0.04
Listeriosis 864 0.26
Lyme disease
Total 33,666 10.34
Confirmed 23,558 7.23
Probable 10,108 3.10
Malaria 1,748 0.53
Measles
Total 375 0.11
Indigenous 296 0.09
Imported 79 0.02
Meningococcal disease
All serogroups 327 0.10
Serogroups ACWY 100 0.03
Serogroup B 81 0.02
Other serogroups 23 0.01
Unknown serogroup 123 0.04
Mumps 2,515 0.77
Novel Influenza A virus infections 14 0.00
Paratyphoid fever ** 133 0.04
Pertussis 15,609 4.77
Plague 1 0.00
Poliomyelitis, paralytic — —
Poliovirus infection, nonparalytic — —
Psittacosis 22 0.01
Q fever
Total 215 0.07
Acute 178 0.05
Chronic 37 0.01
Rabies
Animal 4,984 1.52
Human 3 0.00
Rubella 4 0.00
Rubella, congenital syndrome — —
Salmonellosis (excluding paratyphoid fever and typhoid fever) †† 60,999 18.64
Severe acute respiratory syndrome-associated coronavirus disease — —
Shiga toxin-producing Escherichia coli (STEC) 15,996 4.89
Shigellosis 16,333 4.99
Smallpox — —
Spotted fever rickettsiosis
Total 5,544 1.71
Confirmed 124 0.04
Probable 5,420 1.67
Streptococcal toxic shock syndrome 371 0.18
Syphilis
Total, all stages §§ 115,045 35.16
Congenital 1,306 34.44
Primary and secondary 35,063 10.72
Tetanus 23 0.01
Toxic shock syndrome (other than Streptococcal) 33 0.01
Trichinellosis 1 0.00
Tuberculosis 9,025 2.76
Tularemia 229 0.07
Typhoid fever 401 0.12
Vancomycin-intermediate Staphylococcus aureus 85 0.03
Vancomycin-resistant Staphylococcus aureus — —
Varicella morbidity 8,201 3.07
Varicella mortality 6 0.00
Vibriosis
Total 2,964 0.92
Confirmed 1,822 0.57
Probable 1,142 0.35
Viral hemorrhagic fevers
Crimean-Congo hemorrhagic fever virus — —
Ebola virus — —
Guanarito virus — —
Junin virus — —
Lassa virus — —
Lujo virus — —
Machupo virus — —
Marburg virus — —
Sabia virus — —
Yellow fever — —
Zika virus
Zika virus disease, congenital ¶¶ 2 0.05
Zika virus disease, non-congenital 79 0.02
Zika virus infection, congenital ¶¶ 8 0.21
Zika virus infection, non-congenital 245 0.07
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • * Reportable in <25 states.
  • † Counts include confirmed and probable dengue cases.
  • § Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm.
  • ¶ Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
  • ** Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • †† Prior to 2018, cases of paratyphoid fever were included as salmonellosis, but beginning in 2018 they are being published as paratyphoid fever.
  • §§ Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); and unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations).
  • ¶¶ Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01).
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
  2. The list of nationally notifiable infectious diseases and conditions for 2018 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2018" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2017 by CSTE for national surveillance, that were implemented in January 2018, including updated surveillance case definitions for anthrax, shiga toxin-producing Escherichia coli, and syphilis. Perinatal hepatitis c virus infection became a new nationally notifiable condition in 2018. While Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) was added to the list of nationally notifiable diseases in 2018, reporting jurisdictions could not submit data for this condition since Office of Management and Budget Paperwork Reduction Act approval was pending during 2018. Publication criteria for the finalized 2018 data are available at https://wonder.cdc.gov/nndss/documents/2018_NNDSS _Publication_Criteria_07122019_updated_09230219.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Annual tables for 2016 and later years are available on CDC WONDER.
  4. Annual summary reports from 1993-2015 are available as published in the MMWR.
  5. NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left).
  6. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a nationally notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Population estimates for incidence rates are July 1st, 2018 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010 - July 1, 2018, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2018), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released June 25, 2019 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2018 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on June 26, 2019 at https://www.census.gov/data-tools/demo/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal Hepatitis B infection (age restriction in numerator is ≤24 months, denominator is <24 months)
    • Perinatal Hepatitis C infection (age restriction in numerator is ≤36 months, denominator is <36 months)

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2018 (National Center for Health Statistics Natality 2018, as compiled from data provided by the Vital Statistics Cooperative Program). The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases. Congenital syphilis data are published in Syphilis Statistics in the Sexually Transmitted Diseases (STD) surveillance report (https://www.cdc.gov/std/syphilis/stats.htm) and in the historical archives of the STD surveillance report (https://www.cdc.gov/std/stats/archive.htm). The STD surveillance report (https://www.cdc.gov/std/syphilis/stats.htm) updates congenital syphilis cases and rates over time.

  7. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
Suggested Citation: Acknowledgement:
  • CDC acknowledges the Local, State, and Territorial Health Departments that collected the data from a range of case ascertainment sources (e.g., health-care providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.